Role of Body Fat Distribution and the Metabolic Complications of Obesity

Michael D. Jensen
Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905

Context: An upper body/visceral fat distribution in obesity is closely linked with metabolic complications, whereas increased lower body fat is independently predictive of reduced cardiovascular risk.

Evidence Acquisition: The measured functions of different fat depots with regards to fatty acid storage and release in health and obesity were reviewed. The adverse effects of experimentally increasing free fatty acid (FFA) concentrations on liver, muscle, pancreatic β-cell, and endothelial function were noted.

Evidence Synthesis: The most dramatic abnormality in FFA metabolism is failure to suppress FFA concentrations/adipose tissue lipolysis normally in response to postprandial hyperinsulinemia. Upper body subcutaneous fat delivers the majority of FFA to the systemic circulation under postabsorptive and postprandial conditions. In upper body obesity, portal FFA concentrations resulting from both systemic and visceral adipose tissue lipolysis may be significantly greater than arterial FFA concentrations, exposing the liver to even greater amounts of FFA. Visceral fat also releases sufficient IL-6 to increase portal vein IL-6 concentrations, which can affect hepatic metabolism as well.

Conclusions: Lower body, upper body subcutaneous, and visceral fat depots have unique characteristics with regards to fatty acid metabolism. Selective dysregulation of these depots probably plays an important role with the metabolic complications of obesity. (J Clin Endocrinol Metab 93: S57–S63, 2008)

Defining Fat Depots

The various fat depots have unique characteristics. These range from the smaller, specific depots that track with visceral fat such as pericardial (19) and buccal (20) fat, to subdivisions of large depots like superficial and deep abdominal subcutaneous fat (21, 22). Intraperitoneal fat includes omental and mesenteric (visceral) depots, both of which drain into the portal vein, along with perinephric fat, which drains into the systemic circulation. The lower body fat is commonly demarcated as all adipose tissue caudad to the inguinal ligament anteriorly and the iliac crest posteriorly. Subcutaneous lower body fat includes gluteal and leg depots, which may have differing characteristics (23), and adipose tissue in between the major muscle groups (so-called marbling) (24). Upper body subcutaneous fat includes superficial and deep truncal depots noted previously, upper extremity fat, and breast adipose tissue in women. One reasonably utilitarian approach is to characterize human body fat compartments as lower body fat, upper body subcutaneous fat.
fat, and intra-abdominal/visceral fat. An advantage of this approach is that the compartments can be measured readily using dual-energy x-ray absorptiometry and a single-slice computed tomography or magnetic resonance image of the abdomen (25, 26). Those investigators with greater access to magnetic resonance imaging and considerable technical time to analyze the scans are able to define better the numerous specific fat depots (22).

**Visceral Fat and Metabolic Complications—Cause and Effect?**

Although the explanation for the strong association between visceral fat and metabolic abnormalities is not known, one hypothesis is that visceral fat produces and releases substances that cause metabolic abnormalities (27–29). More recently, an alternative hypothesis has been proposed. This concept is that visceral fat is another “ectopic fat depot” (30, 31) not unlike pericardial fat (19), cheek fat (20), intramyocellular triglyceride (imTG) (32), and elevated hepatic triglyceride (33). In this paradigm, ectopic triglyceride accumulation is the result of energy imbalance wherein body fat stores exceed the functionally normal storage capacity of sc adipose tissue depots. The potential abnormal function(s) of sc fat includes a reduced ability to take up and store circulating triglyceride fatty acids along with excess free fatty acid (FFA) release under some conditions. This concept includes the abnormalities caused by greater infiltration of adipose tissue with inflammatory cells, excess release of potentially harmful cytokines, and reduced release of beneficial adipokines.

**Normal Function of the Major Adipose Tissue Depots—Fatty Acid Metabolism**

*In vivo* measures of systemic and regional adipose tissue FFA release have been performed in normal weight adult women and men under a variety of circumstances. Likewise, measures of dietary fatty acid storage and direct FFA storage in regional fat have been reported.

Under postabsorptive conditions, upper body sc adipose tissue in both men and women is more lipolytically active than lower body adipose tissue as measured by FFA release per kg fat (34). In response to hyperinsulinemia (35) and meal ingestion (34, 36), leg FFA release is much more readily suppressed than upper body sc fat. FFA release from the splanchic bed, a surrogate measure of visceral adipose lipolysis, is relatively resistant to suppression by hyperinsulinemia and meal ingestion (34, 35). The inability to measure FFA release directly into the portal vein in humans allows only indirect estimates of visceral adipose tissue lipolysis (37), and, thus, the rates of visceral adipose tissue lipolysis relative to visceral fat mass are not known.

Adipose tissue is also a major site of meal fatty acid storage. Normal weight men and women store roughly similar proportions of dietary fat in sc and visceral fat (38–41), but in men this is at the cost of greater triglyceridemia (40, 41).

Paralleling the pattern of FFA release, the uptake of dietary fatty acids into upper body sc fat (milligram meal fat per gram of adipose tissue lipid) is more efficient than the uptake in lower body sc fat in normal weight men and women (38–40). Likewise, visceral fat stores more dietary fat (milligram meal fat per gram of adipose tissue lipid) than either upper body sc or lower body sc fat in both normal weight men (42) and women (38, 43). This finding would argue that, at least in normal weight adults, visceral adipose tissue is more lipolytically active on a per unit weight basis than sc fat. However, the impact of visceral adipose tissue lipolysis on overnight postabsorptive hepatic FFA delivery appears to be very limited due to the typically small visceral fat mass in lean adults (37).

An unexpected recent finding is that systemic FFA can be restored back into sc and visceral fat without going through the very low-density lipoprotein (VLDL)-triglyceride pathway (44, 45). Although the fraction of systemic FFA restored in whole body sc adipose tissue is relatively small (~3% for men and 9% for women), this process may play a role in the shuttling of FFA from one depot to another in such a manner as to modify fat distribution.

Subcutaneous and visceral fat combined store approximately 50% of dietary fat (38, 40). Thus, for nonobese adults consuming a typical U.S. diet containing 100 g fat and maintaining stable body composition, adipose tissue must also net release 50 g triglyceride/d as FFA for total and regional fat mass to remain stable. Understanding this balance is possible to estimate the net FFA release from regional fat depots by measuring meal fatty acid storage. Adipose tissue also takes up VLDL-triglyceride (46, 47) and FFA directly (44, 45), and, thus, total regional adipose FFA release exceeds net FFA release when assessed relative to dietary fat storage. These concepts become relevant when considering the role of different fat depots in delivering FFA to the portal and systemic circulation in obesity.

**Abnormalities in Fatty Acid Metabolism in Upper Body Obesity**

**Adipose tissue storage of fatty acids**

Adipose tissue is considered a major site for clearance of triglyceride-rich lipoproteins. To the extent that this function might be impaired in obesity, especially upper body obesity, this could contribute to the hypertriglyceridemia associated with this condition. Recent studies have examined whether upper body sc fat in persons known to have disordered lipid metabolism has a reduced ability to take up triglycerides, which could contribute to postprandial hypertriglyceridemia. These studies failed to show an impaired ability of upper body sc fat to take up and store triglycerides (48). Similarly, the regional storage of dietary fat has been looked at in obese men and women (43, 49). Increasing amounts of leg fat in women is associated with greater storage of dietary fat in lower body adipose tissue, whereas this is not the case for visceral fat (43). Upper body sc adipose tissue stored dietary fat in a manner different still from visceral or leg adipose tissue. Obese men store a much smaller proportion of dietary fat in sc than do obese women, with the difference being most marked between lower body obese women and obese men (49).

The adipose tissue clearance of VLDL-triglyceride fatty acids (46) and storage of systemic FFA (44, 45) has been examined in
obesity. Depending on how the data are expressed, there is some evidence for the reduced disappearance of VLDL-triglycerides across abdominal sc adipose tissue in obesity (46). Whether it is the lower body or visceral adipose tissue storage of VLDL-triglycerides that is altered in obesity, especially upper body obesity, is unknown, as is the fraction of VLDL-triglyceride fatty acids that are restored in adipose tissue.

Direct storage of systemic FFA back into adipose tissue in the postabsorptive state is remarkably different between men and women (45) and between different adipose tissue depots (44). Women with upper body obesity store a substantially greater portion of systemic FFA in lower body adipose tissue than do upper body obese men (45). However, direct FFA storage in upper body sc fat is similar in both upper body obese men and women. The greater clearance of FFA by lower body sc adipose tissue in women should theoretically limit the excess FFA available to muscle, liver, and other sites where FFA could reduce insulin sensitivity. Whether whole body and regional FFA storage is altered in lower body obesity is unknown, although women with lower body obesity tend to have normal FFA kinetics in any case (50–52).

Adipose tissue release of FFA

Whole body FFA release is increased in upper body obesity under postabsorptive (50, 51) and postprandial (36, 52) conditions. Except in metabolically uncontrolled obesity and type 2 diabetes, fasting FFA concentrations/flux in upper body obese is only about 30% greater than in lean or lower body obese adults (50). This is not a large difference, given that the day-to-day variability of FFA concentrations/kinetics is approximately 30% under uncontrolled dietary conditions (53) and approximately 15% with conditions of careful dietary control (54). These relatively small differences in overnight postabsorptive whole body lipolysis may not be the best explanation for the link between upper body/visceral obesity, FFA, and the metabolic complications of obesity. However, there are conditions under which FFAs are vastly and routinely different in upper body obesity.

The most consistent finding with regards to adipose tissue lipolysis is that of much greater FFA release during hyperinsulinemia in upper body/visceral obesity compared with the nonobese or lower body obese state (36, 50, 52). The excess postprandial FFA release results in elevated postprandial FFA concentrations [~3-fold greater in upper body obese than lower body obese (36, 52)]. By definition, this implies that adipocytes in upper body obesity are resistant to the antilipolytic effects of insulin. The explanation for this resistance is not clear. Some have argued that the enlarged abdominal or visceral adipocytes seen in upper body obesity are inherently resistant to insulin (55, 56). Certainly, weight loss via diet and exercise, which reduce fat cell size, also improves insulin regulation of lipolysis (57), whereas surgical removal of abdominal sc fat via liposuction (no decrease in fat cell size) does not (58). On the other hand, surgical removal of omental fat during bariatric surgery was associated with significantly greater improvement in fasting plasma glucose and insulin concentrations along with a significantly greater decrease in body mass index than a control group that did not undergo resection of omentum (59). Unfortunately, we do not know whether regulation of adipose tissue lipolysis was affected by omentectomy or whether removal of visceral fat vs. greater relative weight loss accounted for the observed effects on insulin and glucose.

To provide a perspective on the relationship between plasma insulin concentrations vs. leg, splanchnic, and upper body sc adipose tissue FFA (palmitate) release, data from Meek (35) and Guo (36) et al. are plotted in Figs. 1–4 using a logarithmic display format (60). In insulin-sensitive nonobese adults, the relative suppression of FFA release from the splanchnic bed as a result of higher plasma insulin concentrations (35) seems blunted compared with leg and upper body sc fat (Fig. 1). Figures 2–4 depict the relationship between plasma insulin concentrations and palmitate release from upper body sc fat, leg fat, and the splanchnic bed in these same nonobese volunteers (35) compared with lower body obese and upper body obese women (36) studied before and during meal ingestion. Whereas the data points from nonobese and lower body obese (both more insulin sensitive) tend to display the same general relationship, the data points from upper body obese women (more insulin resistant) are displaced upwards, implying that each depot is to some degree insulin resistant. Because the total amount of FFA released from upper body sc fat is so much greater than that from the leg and splanchnic bed, however, insulin resistance in this depot appears to be quantitatively more important.

The implications of excess adipose tissue lipolysis in upper body obesity deserve attention. Most of the studies examining the adverse effects of experimentally elevating plasma FFA concentrations have used the paradigm of assessing their effect on insulin-stim-
ulated glucose disposal (61), insulin-suppressed glucose (62), and hepatic triglyceride production (63), as well as insulin-stimulated tissue blood flow (64). Thus, it is reasonable to consider that high postprandial FFA concentrations are particularly relevant to the metabolic abnormalities seen in obesity. Given the association between visceral fat metabolic complications of obesity (16, 65) and the finding of greater splanchnic FFA release during hyperinsulinemia (35), it is tempting to blame visceral adipose tissue lipolysis for elevated postprandial FFA concentrations in upper body obesity. However, in vivo studies have shown this not to be the case.

In lean men and women, leg adipose tissue lipolysis contributes approximately 15–20% of basal, systemic FFA release (34, 35). In obese men and women, the average was 28% of FFA release (36, 37). Because leg adipose tissue lipolysis is so sensitive to insulin (35) and meal (34, 36) suppression, it does not seem to contribute to the elevated postprandial FFA in obesity. Upper body sc adipose tissue FFA release accounts for the majority (>60%) of systemic FFA under basal (37, 66) and insulin-suppressed conditions (35, 36, 67). The greater postprandial FFA concentrations in upper body obesity compared with lower body obesity could be entirely accounted for by excess FFA release from upper body sc fat (36), not visceral fat.

However, the net release of new FFA into the systemic circulation from the splanchnic bed does not fully reflect visceral adipose tissue lipolysis. The liver takes up a considerable fraction of FFA in the portal vein (68, 69). In addition, some of the FFA entering the splanchnic bed via the arterial supply are taken up by nonhepatic tissues before they can enter the portal vein. Fasting FFA concentrations in the portal vein have not been found to be substantially greater than those typically seen in the arterial circulation (70). That said, the appearance of new FFA in the hepatic vein is probably a direct measure of the contribution of visceral adipose tissue lipolysis to systemic FFA availability and, thus, plasma FFA concentrations. We found that only 6–17% of systemic FFA come from the splanchnic bed under overnight postabsorptive conditions (34, 35) but can increase to 40% during hyperinsulinemia (35). This might indicate either that visceral fat is very resistant to insulin’s antilipolytic effects when compared with sc fat [as noted in dogs (71)] or that the spillover of fatty acids from the hydrolysis of triglyceride-rich lipoproteins is a special issue in the splanchnic bed (72). In either case the liver is probably exposed to significantly greater FFA concentrations than the periphery during hyperinsulinemia, and this portal-systemic difference may well be exaggerated in upper body/visceral obesity.

**Effects of increased FFA concentrations**

**FFA and the liver**

The ability of insulin to suppress glucose production is thought to be through a combination of direct insulin action on the liver and an indirect action via suppression of
Elevated systemic FFA and β-cell dysfunction

It is established that fatty acids can have adverse effects on islet insulin content (77, 78). One theory is that type 2 diabetes develops as part of a biphasic β-cell response to excess FFA (78, 79). A number of mechanisms have been proposed to mediate the toxic effects of excess intracellular fatty acids, but species differences in how β-cells respond to fatty acids make it difficult to translate directly animal and cell model systems to human type 2 diabetes. Because the pancreas is not downstream of the portal vein, any adverse effects of FFA on human insulin secretion in visceral obesity would largely be an effect of abnormal regulation of sc adipose tissue lipolysis.

Muscle and FFA

The preferential oxidation of fatty acids by muscle mitochondria and the resultant competition with glucose (the Randle cycle) is a suggested mechanism for fatty acid-induced insulin resistance (80). FFA elevation has also interrupted muscle insulin receptor substrate and phosphatidylinositol 3-kinase insulin-mediated glucose uptake independent of their oxidative role, contributing to peripheral resistance in a novel pathway (81). imTG accumulation may provide a link between extracellular FFA and the intramyocellular environment because imTG correlates well with insulin resistance, and FFAs are a precursor of imTG (82, 83). The precise mechanism(s) is not entirely known at present, but interesting possibilities include actions of diacylglycerols, ceramides, and long-chain acyl-coenzyme A, themselves as intracellular mediators of impaired insulin signaling. Again, muscle is exposed to systemic FFA concentrations, which predominantly originate from upper body sc fat. Thus, the adverse effects of FFA on muscle insulin action in obesity are largely an effect of abnormal regulation of sc adipose tissue lipolysis.

Adipokines in upper body obesity

A large number of substances are known to be produced by adipose tissue. Collectively, these have been termed adipokines, and their purported function and role in the metabolic complications of obesity are reviewed in a companion article (84). To date, the only adipokine documented to be uniquely overproduced by visceral fat is IL-6 (29). Adiponectin concentrations are reduced in adults with excess visceral fat, but strangely enough in obese women, concentrations correlate positively with leg fat mass (85). Whether this indicates that adiponectin is preferentially produced by leg fat or that women with greater amounts of leg fat are more insulin sensitive and, thus, have greater adiponectin concentrations, is unknown.

Summary

An upper body/visceral fat distribution in obesity is strongly linked with the metabolic complications of obesity. Evidence
from studies that manipulate FFA concentrations suggests that a number of these metabolic abnormalities are caused by elevated FFAs. Because the most consistent abnormality in FFA metabolism is failure to normally suppress FFA in response to insulin/meal ingestion, we suggest that postprandial elevations of FFAs are especially problematic in obesity. FFAs released from visceral fat make a minor contribution to systemic FFA concentrations, which are the obligate concentrations affecting muscle, pancreatic β-cells, and vascular endothelium. In persons with visceral obesity, omental and mesenteric fat may play a special role in delivering both excess FFA and IL-6 to the liver. We do not yet understand why upper body sc fat, the source of the majority of systemic FFAs, is dysregulated in upper body obesity. Weight loss via diet/exercise is able to improve the regulation of FFA metabolism (57), whereas simply removing sc fat does not (58).

Acknowledgments

Address all correspondence and requests for reprints to: Michael D. Jensen, M.D., Endocrine Research Unit, Mayo Clinic, 200 1st Street, Room 5-194 Joseph, Rochester, Minnesota 55905. E-mail: jensen@mayo.edu.

This work was supported by American Diabetes Association (ADA no. 7-06-DCS-03) and the United States National Institutes of Health Grants DK45343 and DK40484.

Disclosure Statement: The author has nothing to disclose.

References
